Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study

BACKGROUND: Capecitabine plus cisplatin (XP) is recognized as one of the global standard first-line chemotherapy regimens for patients with metastatic gastric cancer (mGC). Recent multinational phase III trials in mGC have been conducted with XP as the control arm, although no data on XP in Japanese...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Yamaguchi, Kensei, Sawaki, Akira, Doi, Toshihiko, Satoh, Taroh, Yamada, Yasuhide, Omuro, Yasushi, Nishina, Tomohiro, Boku, Narikazu, Chin, Keisho, Hamamoto, Yasuo, Takiuchi, Hiroya, Komatsu, Yoshito, Saji, Shigehira, Koizumi, Wasaburo, Miyata, Yoshinori, Sato, Atsushi, Baba, Eishi, Tamura, Takao, Abe, Takashi, Ohtsu, Atsushi
Format: Artigo
Langue:Inglês
Publié: Springer Japan 2012
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3627028/
https://ncbi.nlm.nih.gov/pubmed/22782463
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10120-012-0167-0
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires